Shutoku Matsuyama - Concepedia

Author

Shutoku Matsuyama

National Institute of Infectious Diseases ORCID

Also Known As

Norio Yamamoto, S Matsuyama, S. Matsuyama, Shutoku MATSUYAMA, Shutoku Matsuyama

Publications

8.4K

Citations

H-Index

Concepts

All Affiliations

National Institute of Infectious Diseases Nippon Veterinary and Life Science University National Center of Neurology and Psychiatry Murayama Medical Center The University of Tokyo

About

Shutoku Matsuyama is an author at National Institute of Infectious Diseases specializing in medicine, virology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	35	6.4K
2	Public Health	2	2	65
3	Biomolecular Engineering	2	2	139
4	Engineering	1	1	101
5	Biochemistry	1	1	84

Shutoku Matsuyama

Publications

8.1K

Citations

H-Index

Page 1

	Year	Citations
Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells Shutoku Matsuyama, Naganori Nao, Kazuya Shirato, Proceedings of the National Academy of Sciences Viral EvolutionNovel BetacoronavirusViral DiagnosticsEmerging Infectious DiseasesRespiratory Diseases	2020	1.6K
Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2 Shutoku Matsuyama, Noriyo Nagata, Kazuya Shirato, Journal of Virology Protease InhibitorsEfficient ActivationVirus StructureViral ReplicationVirus Infection	2010	838
Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry Miyuki Kawase, Kazuya Shirato, Lia van der Hoek, Journal of Virology Protease InhibitorsMolecular VirologyImmunologyViral PathogenesisCell Surface	2012	554
Middle East Respiratory Syndrome Coronavirus Infection Mediated by the Transmembrane Serine Protease TMPRSS2 Kazuya Shirato, Miyuki Kawase, Shutoku Matsuyama Journal of Virology Protease InhibitorsMolecular VirologyVirus EntryPathogenesisViral Pathogenesis	2013	477
Development of Genetic Diagnostic Methods for Detection for Novel Coronavirus 2019(nCoV-2019) in Japan Kazuya Shirato, Naganori Nao, Harutaka Katano, Japanese Journal of Infectious Diseases Virus EpidemiologyViral DiagnosticsDiagnosisGenetic Diagnostic MethodsCovid-19	2020	465
Role of Endosomal Cathepsins in Entry Mediated by the Ebola Virus Glycoprotein Kathryn L. Schornberg, Shutoku Matsuyama, Kirsten Kabsch, Journal of Virology Virus StructureMolecular VirologyCatl Prime GpCathepsin BPathogenesis	2006	416
Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay Mizuki Yamamoto, Shutoku Matsuyama, Xiao Li, Antimicrobial Agents and Chemotherapy	2016	351
Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection Shutoku Matsuyama, Makoto Ujike, Shigeru Morikawa, Proceedings of the National Academy of Sciences Protease InhibitorsInflammationMajor ProteaseLung InflammationPathogenesis	2005	329
The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells Shutoku Matsuyama, Miyuki Kawase, Naganori Nao, Journal of Virology	2020	294
Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry Kazuya Shirato, Miyuki Kawase, Shutoku Matsuyama Virology Virus StructureCell-surface Tmprss2Wild-type Human CoronavirusesPathogenesisViral Pathogenesis	2017	242

Page 1